MARKET

KZIA

KZIA

Kazia Therapeuti
NASDAQ
5.37
-0.12
-2.19%
After Hours: 5.37 0 0.00% 19:30 11/19 EST
OPEN
5.69
PREV CLOSE
5.49
HIGH
5.80
LOW
5.30
VOLUME
279.54K
TURNOVER
--
52 WEEK HIGH
17.40
52 WEEK LOW
4.860
MARKET CAP
83.19M
P/E (TTM)
-0.8851
1D
5D
1M
3M
1Y
5Y
1D
Kazia Therapeutics: Buy Rating Maintained Despite Price-Target Cut to $20 on Paxalisib Promise
TipRanks · 12h ago
Kazia Therapeutics Files Fiscal 2026 Annual Report
TipRanks · 17h ago
Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026
PR Newswire · 19h ago
Weekly Report: what happened at KZIA last week (1109-1113)?
Weekly Report · 3d ago
Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader
PR Newswire · 11/12 12:00
Weekly Report: what happened at KZIA last week (1102-1106)?
Weekly Report · 11/09 09:07
Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards
PR Newswire · 11/05 12:00
Kazia Therapeutics Delays Annual Filing Amid Controls Review
TipRanks · 11/02 22:41
More
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.

Webull offers Kazia Therapeutics Ltd (ADR) stock information, including NASDAQ: KZIA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZIA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KZIA stock methods without spending real money on the virtual paper trading platform.